Licensing Opportunity for an Automated Digital Pathology Device

Licensing Opportunity for Automated Digital Pathology Device

Are you interested in licensing an automated digital pathology device? The National Cancer Institute (NCI) is seeking licensees to develop an automated digital pathology device that could be used for biopsy sample processing and applicable to diagnoses of various disease indications, including cancer and infectious diseases.

NCI recognized the need for automation of the techniques used in processing pathology samples and acquisition of digital images to make them amenable with high-throughput approaches like artificial intelligence (AI) analysis. These automated techniques are required because demand for AI, such as three-dimensional (3D) reconstruction, in digital pathology has increased and this demand cannot be met by the time-consuming manual process.

Inventors at NCI are developing an automated device with integrated tissue sectioning, staining, scanning, and high-throughput capability. This device integrates pathology sample processing with optical scanning and digital image acquisition. It will facilitate processing and imaging of large volumes of pathology samples, save time through increasing reproducibility and minimizing errors, and will be compatible with high-throughput processes such as AI analysis of digital pathology images and 3D reconstruction.

If you are interested in licensing this technology, please view the abstract for more information.